跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ALK-1 inhibitors (cancer)
首页
药物
ALK-1 inhibitors (cancer)
ALK-1 inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors
申请人: VERNALIS CAMBRIDGE LTD
优先权: 2003
US
4 件公开
Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
申请人: KOHNO TAKASHI
优先权: 2011
US
2 件公开
Pyrazolopyrimidine compounds and their use in medicine
申请人: VERNALIS CAMBRIDGE LTD
优先权: 2003
US
Pyrimidothiophene compounds
申请人: VERNALIS CAMBRIDGE LTD
优先权: 2003
CN
PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS
申请人: VERNALIS R&D LTD
优先权: 2005
US
ALK-5 inhibitors and uses thereof
申请人: SUMITOMO PHARMA ONCOLOGY INC
优先权: 2021
CN
ALK-5 inhibitors and uses thereof
申请人: SUMITOMO PHARMA ONCOLOGY INC
优先权: 2021
CN
ALK-5 inhibitors and uses thereof
申请人: SUMITOMO PHARMA ONCOLOGY INC
优先权: 2022
US
药物
反馈